Surgical Science Sweden AB (publ) (STO:SUS)

Sweden · Delayed Price · Currency is SEK

33.52

-1.22 (-3.51%)

At close: Dec 5, 2025

-77.62% (1Y)

Market Cap	1.71B
Revenue (ttm)	975.04M
Net Income (ttm)	69.83M
Shares Out	51.03M
EPS (ttm)	1.37
PE Ratio	24.49
Forward PE	13.29
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,200,871
Average Volume	1,977,185
Open	34.76
Previous Close	34.74
Day's Range	33.14 - 35.38
52-Week Range	24.00 - 192.40
Beta	0.60
RSI	21.51
Earnings Date	Nov 13, 2025

About STO:SUS

Surgical Science Sweden AB (publ) develops and markets virtual reality simulators for evidence-based medical training in Europe, North and South America, Asia, and internationally. The company offers Angio Mentor simulator for endovascular training; BRONCH Express, a portable version of BRONCH mentor simulator; ARTHRO Mentor for arthroscopic surgery skills acquisition; BRONCH Mentor, a simulator for optimizing bronchoscopy training; GI Mentor, a simulator for GI Endoscopy; HYST Mentor for True-To-Life diagnostic and therapeutic hysteroscopy tra... [Read more]

Industry Health Information Services

Sector Healthcare

Founded 1997

Employees 274

Stock Exchange Nasdaq Stockholm

Ticker Symbol SUS

Full Company Profile

Financial Performance

In 2024, STO:SUS's revenue was 884.09 million, an increase of 0.14% compared to the previous year's 882.85 million. Earnings were 131.65 million, a decrease of -43.73%.

Financial Statements

Surgical Science Sweden AB (publ) (STO:SUS)

About STO:SUS

Financial Performance

News

Surgical Science Sweden AB (publ) 2025 Q3 - Results - Earnings Call Presentation

Surgical Science Sweden AB (SUSRF) Q3 2025 Earnings Call Highlights: Record Sales Amidst ...

Q3 2025 Surgical Science Sweden AB Earnings Call Transcript

Surgical Science Sweden AB (publ) (SUSRF) Q3 2025 Earnings Call Transcript